Ingrid Krücken, Vice President of Europa Donna – The European Breast Cancer Coalition, shared on LinkedIn:
“EAA Fall Convention, 19-20 November 2026, INFARMED, Lisbon, Portugal.
I had the honour of representing EUROPA DONNA – The European Breast Cancer Coalition at an exceptional gathering of expertise and perspectives at the HTA EAA Fall Convention 2026.
We kicked off the Convention with a session dedicated to medical devices and their specificities and challenges featuring valuable first-hand insights from a developer and a representative of the European Commission.
What makes a discussion truly valuable is not only the importance of the topics addressed, but above all the quality, diversity and depth of the voices around the table.
The Convention brought together an outstanding line-up of speakers from across the European healthcare ecosystem, representing patient organisations, European institutions, HTA bodies, clinical practice and industry.
We opened the Convention with a dedicated session on medical devices and their specificities, benefiting from first-hand insights from amongst other a medical device developer and a representative of the European Commission.
Among the many valuable exchanges, I appreciated the opportunity to co-facilitate a two-hour breakout session with Dario Trapani and James Ryan on the JCA report on Camezistrant, a next-generation oral SERD for patients with HR+/HER2− locally advanced or metastatic breast cancer. The SERENA-6 trial explores a new approach: detecting emerging ESR1 mutations through ctDNA and switching to camizestrant before disease progression becomes visible.

The contributions of the group, having the opportunity to engage directly with the developer, ask questions and analyse an actual JCA report together, enriched by Dario’s clinical expertise was a truly unique learning experience.

The multi-stakeholder approach is essential if we want the new European HTA framework to deliver on its promise of more equitable, meaningful and timely access to innovation.
A big thank you to EAA and EPF for bringing together such an impressive group of experts and creating space for these important conversations.”
Dario Trapani, Medical Oncologist at the European Institute of Oncology (IEO), added:
“It’s been just wonderful to co-facilitate the breakout session on the new breast cancer EU JCA at the EAA – European Access Academy and ECF, hosted by INFARMED, Lisbon with all the stakeholders sharing knowledge, expertise and insights around the table!
I highly valued the input from who has contributed to develop the JCA, but, mostly navigation the PICO formulation and potential areas for improvement, particularly how important is to expand patient-relevant outcomes, not only for the general public, but to eventually inform the national HTA exercise in health economic and population health impact modelling.
Looking for contributing to this conversation, and working together as a community more!”
You can also read:
